COMP <GO>
KNSA vs AMRX // ALTMAN Z-SCORE & DEBT/EQUITY
Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) VS. Amneal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: KNSA 7
— AMRX 5
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: KNSA
LAST: $90.80 (-1.56%) • MKT CAP: $7.13B
balance-sheet
24.45
LAST: $20.44 (-4.97%) • MKT CAP: $7.12B
balance-sheet
3.83
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. AMRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | AMRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 36.90% | +51.60 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 14.10% | -4.20 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 21.4x | +73.60 | AMRX | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 3.63% | -1.85 | AMRX | /fcf-yield <GO> |
| Operating Margin | 11.40% | 13.10% | -1.70 | AMRX | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 2.40% | +6.30 | KNSA | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 8.00% | +52.10 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 24.45 | 3.83 | +20.62 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 51.1 | +6.10 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.08 | +0.03 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 96.0x | +13.10 | AMRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.13B | $7.12B | $15.1M | KNSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | AMRX REV | KNSA GROSS % | AMRX GROSS % | KNSA FCF | AMRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $3.02B | 88.5% | 36.9% | $136.4M | $269.9M |
| FY 2024 | $423.2M | $2.79B | 85.6% | 36.5% | $25.4M | $243.2M |
| FY 2023 | $270.3M | $2.39B | — | — | $1.1M | $237.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
AMRX // BETA 1.08